Related Experiment Video
Updated: Aug 19, 2026

Evaluation of Hepatic Glucose Production in a Polycystic Ovary Syndrome Mouse Model
Published on: March 5, 2022
Metabolic alterations and cardiovascular risk factors in the polycystic ovary syndrome
R Pasquali1, L Patton, U Pagotto
1Department of Internal Medicine, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. renato.pasquali@unibo.it
Abstract:
Available literature indicates that polycystic ovary syndrome (PCOS) represents a condition with a high prevalence of the metabolic syndrome, a greater and precocious appearance of glucose intolerance states, including type 2 diabetes mellitus, and a potentially greater risk for cardiovascular diseases. With respect to metabolic disorders, however, there is also emerging evidence that they are more prevalent in PCOS rather than in the general population, and that there are regional differences in the world, depending on lifestyle and other environmental factors. This evidence should be taken into consideration in future strategies focusing on prevention of metabolic and cardiovascular disorders in PCOS, not only on treatment of infertility and signs of androgen excess.
Related Concept Videos
Coronary Artery Disease I: Introduction
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Type II Diabetes I: Introduction
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Oogenesis
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

